NCT01476085View on ClinicalTrials.gov

Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Cancer
Interventions
RADIATION

ML10

\[18F\]ML10 radioligand apoptosis biomarker

Trial Locations (1)

W12 0NN

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01476085 - Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL) | Biotech Hunter | Biotech Hunter